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1. Introduction 
The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text-Revision (DSM-
IV-TR) section on anxiety disorders includes several major disorders: generalized anxiety 
disorder (GAD), obsessive-compulsive disorder (OCD), panic disorder, specific phobia, 
social anxiety disorder (SAD), and posttraumatic stress disorder (PTSD) (DSM-IV-TR, 2000). 
Anxiety disorders are the most prevalent  of all  psychiatric disorders, with an estimated 
prevalence of 2% to 18% worldwide (Wittchen & Jacobi, 2005).  Specific phobias have a 
lifetime prevalence of 12.5%; the lifetime prevalence for GAD, OCD, panic disorder, SAD, 
and PTSD are 5.7%, 1.6%, 4.7%, 12.1%, and 6.8%, respectively (Kessler et al., 2005). 
Anxiety disorders mostly begin at an early age, significantly impair multiple areas of 
development and life, and are associated with numerous adverse consequences such as 
school failure, unemployment and underemployment, academic underachievement, 
interactional and marital problems, and excessive use of health care facilities (Demyttenaere 
et al., 2004; Wittchen & Jacobi, 2005). Although anxiety disorders are highly treatable disease 
the majority of the patients are underdiagnosed or do not receive adequate treatment.   
The goal for the treatment of Anxiety disorders is achieving and sustaining remission 
complete resolution of symptoms and restoration of presymptomatic functioning level. 
However, a significant number of patients do not fully respond to an adequate trial of first 
line treatment with an serotonin reuptake inhibitors (SRIs) . For example, at least 40% to 
60% of OCD patients still exhibit symptoms after treatment (Pallanti & Quercioli, 2006). 
SRIs are currently the first-line pharmacotherapy for most anxiety disorders (Demyttenaere 
et al., 2004). Benzodiazepines are widely used for panic disorder, GAD, and SAD, but they 
are associated with unwanted cognitive side effects, a withdrawal syndrome, and potential 
for abuse. Use of tricyclic antidepressants and monoamine oxidase inhibitors is limited by 
their adverse side effect profiles.  There are also new drugs that modify the Ǆ-aminobutyric 
acid (GABA)-ergic, serotonergic, and glutamatergic receptor complexes and established 
drugs with anxiolytic properties such as  antipsychotics and anticonvulsants.  
Approximately a few of the patients who receive treatment  are fully symptomatic remitted 
(Wittchen & Jacobi, 2005; Craske et al., 2005). 
Even in those who had response to treatment, remission cannot be achieved. There is no 
consensus on the operationalization of response, partial response, remission for each anxiety 
disorder (Ballenger, 2001). It remains important also to develop consensus on different 
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levels of non response  ranging from failure respond to first line therapy to failure respond 
to complex procedures. The best definition for treatment resistance is still inadequate 
(Pallanti et al., 2002). A treatment-resistant patient could be defined as a patient who had a 
standard treatment with at least two antidepressants for a minimum of 6 weeks without 
response (Bandelow & Rüther, 2004). 
This chapter presents a review of the current literature and issues related to GAD  including 
definitions of response and remission, outcome measures and treatment strategies for  
treatment-resistant GAD.  
2. Neurobiology of Generalized Anxiety Disorder (GAD) 
Kessler and colleagues surveyed 5001 subjects and demonstrated that GAD and major 
depression are most likely to occur in the same year and this finding suggests that the 
disorders are probably linked in biologically, but certainly phenomenologically.(Kessler & 
Gruber 2008). The extensive overlap between depression and anxiety means that studying 
the neurobiology of GAD  means also studying the neurobiology of depression. There is a 
variety of evidence implicating the dysfunction of GABA, noradrenergic and serotonerjic 
systems in the expression of GAD. (Ballenger,2001;Gorman and Hirschfeld, 2002). 
Of all of the anxiety disorders, GAD has probably been the least well studied from a genetic 
perspective.  In a recent study of more than 37000 twins from same-sex pairs examined the 
genetic interrelation among GAD, MDD, and neuroticism. The genetic correlation between 
major depression and GAD was very high, suggesting that the same genes influence major 
depression and GAD. The conclusion is that , genetically, MDD and GAD are strongly 
related and have a common connection to the personality trait neuroticism.(Kendler & 
Gardner, 2007) 
Hettema and colleagues studied 2 subtypes of GAD genes, GAD1 and GAD2, and 
determined that variations in GAD1 account for a small proportion of the individual 
differences in neuroticism and may increase susceptibility for MDD and anxiety disorders. 
These preliminary findings are exciting, but replication is needed. (Hettema &An, 2006). 
In neuroimaging studies of GAD, Mathew  and colleagues  compared GAD patients and the 
controls, the GAD subjects had higher ratios of N-acetylaspartate (NAA) to creatine in the 
right dorsolateral prefrontal cortex.(Mathew &Mao, 2004) In an other study, compared with 
the healthy subjects, individuals with GAD had increased activation in the right 
ventrolateral prefrontan cortex when viewing angry faces. (Monk &Nelson, 2006) 
Available research has suggested that GAD is modestly heritable and shares substantial 
genetic variation with major depression and the personality trait neuroticism. Genetic 
association studies are starting to identify promising leads in the search for genes that may 
increase susceptibility to anxiety disorders. Neuroimaging studies in GAD suggest 
increased activity in the brain’s fear circuitry, as well as increased activity in the prefrontal 
cortex, which appears to have a compansatory role in reducing GAD sypmtoms.  
3. Assessment of GAD: Epidemiology, presentation, diagnosis and course 
In the DSM-IV,  the diagnostic features for GAD, include excessive anxiety and worry which 
is difficult to control and pertains to several events or activities. GAD is characterized by 
persistent and excessive anxiety and worry about a number of common events or situations 
(eg, finances, health of self or family, job performance or security) occurring on more days  
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for 6 months or more (DSM-IV). The degree of anxiety is in excess of what would be 
considered reasonably warranted by the reality of the situation. Difficulty controlling worry 
is the cardinal feature of GAD and is associated with at least 3 additional symptoms from a 
list including restlessness or tension, easy fatigability, difficulty concentrating, irritability, 
muscular tension and sleep disturbance. (APA 1980). There are some diagnostic difficulties 
like high rates of comorbidity, confusion in defining the term “excessive” worry and 
duration requirement of 6 months.   Because subthreshold cases that meet all GAD 
diagnostic criteria except for duration of symptoms has demostrated in researches, it is 
suggested that perhaps the duration requirement of 6 months should be revised downward. 
(Kessler & Brandenburg, 2005). 
The main tool used in the clinical setting to assess the severity of symptoms of GAD is the 
Hamilton Anxiety Scale (HAM-A).(Hamilton, 1959). However, the HAM-A isa 14-item, 
clinician-rated scale and is quite time consuming to perform. Recently, scales useful for all 
anxiety disorders as GAD have been developed, such as the Anxiety Sensitivity Index, (ASI) 
b (Reiss et al 1986) Anxiety Sensitivity refers to a person’s tendency to fear anxiety-related 
symptoms due to the belief that there will be some negative outcome as a result of having 
those symptoms.  the ASI is a widely used measure that has been translated into many 
languages.  The validity and the reliability of the Turkish version was also studied and used 
in clinical researches. (Dilbaz 2005)  
Generalized anxiety disorder (GAD) is a relatively common condition (lifetime prevalence 
5.7%,and the 12-month prevalence rate was reported to be 3.1%)  with chronic course which is 
associated with suicidality, significant distress and disability. GAD is an adult onset disorder 
with an oldest median age ( estimated 31 years among US population) at onset of any anxiety 
disorder. Approximately 25% of cases of GAD have an age onset of 20 years and an additional 
50% have an age at onset between 20 and 47. (Kessler &Berglund, 2005). Prevalance is higher 
among female gender ,(twice as often in voman as it does in men) , older age , white adults, 
widowed, separated or divorced with a low income. (Grant &Hasin, 2005) 
Individuals with GAD has a high risk of recurrence. Harvard Research Anxiety Disorders 
project (HARP) the probability of recovery was 0.58 and probability of recurrence among 
patients who had recovered was 0.45 over 12 years. Primary Care Anxiety Project’s  
probability of recovery was 0.39 over 2 years that is a some higher than HARP study. 
Average amount of time that patients were ill during 12 years was %74 in HARP study. 
Comorbid Axis I disorders,(Bruce &Yonkers, 2005) substance use disorders, cluster C 
personality disorders(Yonkers &Dyck, 2000) and female gender(Yonkers& Bruce, 2003) have 
been found to be less likely to remit.  
4. GAD and medical illness 
Patients with GAD often have medical comorbidities such as migraine, rheumatoid arthritis, 
peptic ulcer, irritable bowel syndrome, coronary heart disease, hiperthyroidism, diabetes, 
asthma and cronic obstructive pulmonary disease that may influence treatment choice. 
Activation of the HPA axis and sympathetic pathways can lead to cardiac and metabolik 
alteration and chronic activation of stres response may play a role in the vulnerability to 
chronic medical illnesses in inmay not be dividuals with GAD. (Habib&Gold, 2002; 
Charney, 2004) 
When treating patients with GAD and medical illness, GAD should be treated as an 
independent problem. Controlling GAD may not only improve the patient’s quality of life, 
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but may also improve the physical health which is mediated by the sympathetic nervous 
system and cortisol mechanism. 
5. GAD and psychiatric comorbidities: Depression, bipolar disorder and 
substance abuse 
GAD is frequently comorbid with several psychiatric disorders.  90% have  likelihood of  at 
least 1 psyhiatric disorder in their lifetime , 62.4% had a lifetime history of major depression, 
37.6 % had a lifetime history of alcohol and substance use disorder   and 23.5% to 35.1% had 
at least one other anxiety disorder. The highest comorbidities were major depressive 
disorder (MDD) and dysthymia, while alcohol abuse, social anxiety disorder were also 
common ( (Wittchen & Hoyer, 2001). 
Comorbidity may complicate the diagnosis, treatment and outcome, resulting  with greater 
disability and impairment. (Wittchen & Hoyer, 2001; Goodwin & Gorman, 2002). In a recent 
meta-analysis it is compared the impact of pure GAD and GAD comorbide depression on 
functioning and quality of life. Because patients with comorbidity has more impairment 
overall, it is suggested that clinicians should use clinical interview structured to diagnose for 
the presence of comorbid conditions. (Hoffman &Dukes, 2008) The presence of anxiety 
comorbidity in patients with MDD has also been demonstrated to interfere with the 
treatment response in Sequenced Treatment Alternatives to Relieve Depression (STAR*D)  
study which eveluated 2,876 outpatients. Those who have comorbide anxiety and were 
given first-line pharmacotherapy treatment with citalopram had significantly lower 
remission rates (%22 versus %33)  according to the Hamilton Rating Scale for Depression. 
(Fava & Rush, 2008) 
As with MDD, anxiety comorbidity can worsen the course of bipolar disorder, having a 
greater lifetime risk of suicide attempts ( with current GAD comorbidity it is reported %62; 
with lifetime GAD, %53) and greater risk of comorbide substance use disorder.( Simon 
&Otto, 2004) and higher impulsivity. (Taylor &Hisrshfeld, 2007). 
Because patients with GAD and comorbid disorders are lekely to have more impairment, 
disability, suicidality, poorer functioning and quality of life, fort he best outcome careful 
treatment selection must be chosen. The choice of drug(s) will depend on the severity of 
GAD; other comorbidity; an assessment of the adverse effects; possible drug-drug 
interactions and other risks; and the need for an early onset of action 
6. Treating GAD 
6.1 First-line pharmacotherapy approaches for GAD 
The aims of the treatment of GAD are to reduce the core symptoms of GAD (both the 
psychic and somatic), including restoration of sleep;  to improve patient function and 
quality of life; to treat comorbid disorders—present at the time of diagnosis and those that 
appear over the long term; and to continue treatment for long enough to produce remission 
and, where possible, prevent relapse. Many patients with GAD do not receive adequate 
treatment. Benzodiazepines, selective serotonine reuptake inhibitors (SSRIs), serotonine-
norepinephrine reuptake inhibitors (SNRIs) and cognitive therapy are consistantly effective 
as a first-line treatment. Dose ranges may need to be individualized according to the age, 
medical comorbidity , psychiatric comorbidity and other medications of the patients. 
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Several analyses have shown similar efficacy among antidepressant agents in the 
management of GAD.(Baldwin&Anderson,2005) Of these, SSRIs and SNRIs are generally 
preferred as first-line therapy, as the evidence supporting their efficacy is more robust, and 
they are usually better tolerated than the other classes of antidepressants. More recently, 
sertraline (Dahl &Ravindran, 2005)  and paroxetine has been shown to be efficacious in 
GAD ,and citalopram has demonstrated efficacy in older patients (≥ 60 years of age) with 
GAD (Lenze&Mulsant, 2005).Because of  the prevalence of sexual dysfunction has been 
estimated to be as high as 40% during treatment with SSRIs, it is a common reason for 
treatment discontinuation. 
The SSRIs escitalopram (10–20 mg/day) and paroxetine (20–50 mg/day) have also been 
shown to be effective in the long-term treatment of GAD. (Bielski & Bose, 2005) Relapse 
prevention studies have been reported for both drugs. (Allgulander & Florea, 2006; Stocchi 
&Nordera, 2003). Escitalopram reduced the risk of relapse compared with placebo during 24 
to 72 weeks of randomized treatment following 12 weeks of open-label treatment. Similar 
results were found with paroxetine versus placebo in a shorter study.Essitalopram was also 
showen to exceed the effects of plasebo in an other study , and citalopram was effective in a 
geriatric population with GAD. (Goodman &Bose, 2005; Lenze &Mulsant,2005) 
6.1.2 SNRIs (venlafaxine, duloksetin) 
Venlafaxine, which affects both serotonin and norepinephrine systems, was the first drug 
that is approved fort he treatment of GAD and also has been showen to be effective in 
treating depression. Two placebo-controlled studies have demonstrated the efficacy of 
venlafaxine XR in GAD and have provided that both the psychic and somatic manifestations 
of anxiety can be controlled. One of these study compared venlafaxine (75 mg/da yor 150 
mg/day fixed dose) with buspirone (30 mg7day) treatment for 8 weeks in 365 patients with 
GAD.  A significantly higher response rate as measured on the CGI was seen for venlafaxine 
75 mg/day, compared with either buspirone or placebo after week 1. The mean HAM-A 
anxious mood and tension scores were significantly lower for both doses of venlafaxine XR 
at week 8 compared with placebo , however, the mean total HAM-A scores for all the 
treatment groups compared with placebo were not significant. (Davidson&Dupont, 1999) 
In the second study the efficacy of venlafaxine XR (75 to 225 mg/day) assessed by the HAM-
A  anxiety subscale was statistically higher than  placeboin 238 patients with GAD,  over a 
28-week maintenance period.( Gelenberg& Lydiard, 2000) The results from these  studies 
demonstrate the efficacy of venlafaxine XR in both the short- and long-term treatment of 
GAD, but the optimal dose was not defined. In an 8-week study of 349 patients with GAD , 
venlafaxine at 225 mg/doses was found to have more efficacy than placebo, in reducing 
HAM-A total scores. (Rickels &Pollack, 2000). 
The efficacy of duloksetin, another SNRI, was approved in 2007 for the treatment of GAD. In 
two studies flexible doses of duloksetin (60-120 mg/day) was compared with placebo , 
found significantly greater improvement for both doses on HAM-A total 
scores.(Koponen&Allgulander, 2007). Duloxetine has also  been shown to have long-term 
efficacy among patients with GAD who responded to 26 weeks of open-label treatment; 
administration of duloxetine for a further 26 weeks reduced the risk of relapse compared 
with placebo. (Davidson &Wittchen ,2008). 
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Although benzodiazepines diazepam, alprazolam and lorazepam have showen efficacy in 
controlled trials  and were commonly used in GAD; they must be used with caution because 
of modest abuse potential (Fraser, 1998) interactions with other drugs, including hypnotics 
sedating antidepressants, opiate analgesics, antihistamines, anticonvulsants and alcohol, 
particularly in older patients, falls, memory impaierment, incoordination, drowsiness and 
confusion (Petrovic & Mariman 2003) 
Although benzodiazepines have a rapid onset of action on improving the core symptoms of 
GAD, they are not recommended as monotherapy for depression, dysthymia, obsessive-
compulsive disorder, and posttraumatic stress disorder, which commonly occur with 
GAD.(Ballenger &Davidson,2001; Kessler &Chiu,2005).  
Benzodiazepines are generally recommended only for short-term use and are not 
recommended for first-line long-term treatment of GAD,( Swinson & Anthony 2006) 
although they have a role in the management of acute anxiety (Bandelow B, Zohar,2008; 
Ballenger JC, Davidson,2001) and may have a role in some cases in which somatic 
symptoms are more prominent than psychic symptoms. 
6.1.4 Nonpharmacological treatments (cognitive behavioral therapy-CBT) 
CBT has been used in GAD as a psychological treatment strategy. However, comparisons 
between standard drugs for GAD and psychotherapy are lacking. Although CBT is the most 
effective of the psychological treatments available for GAD, clinical response occurs in less 
than 50% of people receiving this form of therapy (46% versus 14% for control), so unmet 
needs still remain (Hunot &Churchill R, 2007). When GAD is comorbid with depression, 
which is very common, pharmacotherapy with antidepressants is increasingly indicated 
(Ballenger et al., 2001). 
6.2 Treatment comorbidity 
Comorbidity is a critical factor that influence the treatment choice of  GAD. Rickels and 
collegues found that, for GAD patients with significant depressive symptoms, an 
antidepressant drug is more useful than a benzodiazepine. In another study,MDD patients 
with a comorbidity of GAD, venlafaxine XR was found to be more effective than placebo 
and flouksetine.(Silverstone&Salinas, 2001). The data to support appropriate choices in the 
comorbide GAD and bipolar disorder is lacking. Risk of mania with an antidepressant and 
risk of SUD about using benzodiazepines are the likely reasons for inadequate treatments.  
6.3 Treatment in children, adolescents and pregnancy 
For children and adolescents, there are published studies of the treatment of GAD,  
evaluating the SSRIs sertraline, fluoxetine,  fluvoxamine (Walkup & Labellarte 2001;Rynn & 
Siqueland 2001) and  venlafaxine XR. (Sheehan & Keene 2008) These data suggest that these 
agents may be effective in treating the symptoms of GAD in children and adolescents. The 
SSRIs are generally well tolerated in this population. Guidelines from the British Association 
for Psychopharmacology recommend that, in children, pharmacologic treatments should be 
reserved for individuals who have not responded to psychological therapies and careful 
consideration of dosage is also necessary because of the adverse effects.  
In addition, the risk of possible suicidal thoughts or behaviors should be considered and 
these potential adverse effects monitored when any antidepressants are administered in this 
age group.( FDA ,2008). 
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In pregnancy nonpharmacologic treatment such as cognitive-behavioral therapy or 
interpersonal psychotherapy should be employed whenever possible. But it is equally 
important to discuss the risks of the untreated illness to both mother and the infant. So if 
medication is required, the use of SSRIs in the lowest effective dosage for the minimum 
amount of time is preferable in the first-line treatment  because of the data supporting their 
efficacy, minimal need for dose titration and favorable side effect profile. Paroxetine has 
been shown to be efficacious in GAD; however, the US Food and Drug Administration 
(FDA) labeling for its use in pregnancy was reclassified to category D due to possible risk of 
congenital malformations, especially septal defects, when used during the first trimester of 
pregnancy. Newer antidepressants such as venlafaxine XR and mirtazapine are options for 
patients unresponsive or intoleran to SSRIs. Benzodiazepines should be avoided because of 
physiological dependence and withdrawal in the newborn.  
7. Other potentially effective agents 
7.1 Bupropion 
In a recent double-blind, randomized study, which performed on a small sample sizeof 
GAD patients , bupropion XL (150-300mg/day) compared with essitalopram (10-20 
mg/day) for 12 weeks.The primary efficacy measures were the Clinical Global Impression 
of Improvement (CGI-I) and the Hamilton Anxiety Rating Scale (HARS).Bupropion XL is 
found to be demonstrated comparable anxiolytic efficacy to escitalopram in outpatients with 
GAD. These preliminary results needs to be improved further.  
7.2 Atypical antipsychotics 
Several preliminary reports of monotherapy trials of quetiapine versus placebo have 
described efficacy at doses in the range of 50–150 mg/day, (Chouinard & Ahokas A, 2008 ; 
Khan & Joyce 2008) but quetiapine cannot yet be recommended as a routine GAD treatment. 
However the use of quetiapine could be considered after other classes of drugs have proved 
ineffective orwhen certain types of symptoms are present. In the studies by Chouinard, 
quality of life was measured using the Quality of Life Enjoyment and Satisfaction 
Questionnaire (Q-LES-Q)., and the highest  score were seen with quetiapine XR 150 mg and 
paroxetine compared with placebo at week 8 (Chouinard et al 2008) . The efficacious 
application of quetiapine in MDD and GAD ranges from quetiapine monotherapy to 
adjunctive therapy with antidepressants for shortterm and maintenance treatment at a dose 
range between 50–300 mg/day. Despite the often benefi cial sedative effects of quetiapine on 
clinically relevant sleep problems in psychiatric patients, quetipaine is not recommended 
soley as a sleeping agent. Overall, the most recently available evidence on quetiapine 
suggests that it can play a signifi cant role in the management of MDD and GAD.For  
olanzapine or risperidone, it is suggested that the results have been obtained in 
partialresponders to  antidepressants rather than as monotherapy in all patients (Pollack 
&Simon, 2006; Brawman& Knapp, 2005). 
7.3 Antihistamines 
Efficacy of the antihistamines in GAD was established in two studies. (Llorca& Spadone, 
2002; Lader &Scotto, 1998).The antihistamine hydroxyzine appears to have higher  
anxiolytic efficacy than placebo in controlled studies. Because of the side effects (sedation, 
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anticholinergic effects) , slow onset of action, and lack of efficacy for comorbid disorders, 
hydroxyzine was not recommended to be used as first-line therapy in some guidelines. 
(IPAP,2008; Bandelow& Zohar,2008). 
7.4 TCAs 
The tricyclic drug imipramine is effective in GAD but is associated with the usual range of 
tricyclic antidepressant side effects, which limits its use for those who have not responded to 
an SSRI or SNRI.( Baldwin & Anderson ,2005 ; Ballenger &Davidson 2001). Another possible 
second-line antidepressant  includes trazodone (Rickels & Downing ,1993). 
7.5 Buspirone 
The 5HT-1 receptor partial agonist buspirone is found to be effective in the treatment of 
GAD according to controlled studies (Goa &Ward 1986), but  less effective than the 
benzodiazepines, (Laakmann & 1998) venlafaxine or hydroxyzine. Because of side effects 
like dizziness, drowsiness and nause, slow onset of action lack of effectivity on comorbid 
conditions, buspiron is not recommended as first-line treatment for GAD. 
(Bandelow&Zohar,2008) 
7.6 α2δ Ca ++ channel modulators, pregabaline 
The α2ǅ Ca++ channel modulator pregabalin was shown  to have greater efficacy than 
placebo, nearly equal to benzodiazepines and venlafaxine both in the first week and 
maintenance of 6 months in several placebo controlled  studies (Pande&Crockatt,2003; 
Montgomery,2006; Montgomery&Tobias, 2006; Owen,2007). The long-term efficacy of 
pregabalin has also been demonstrated in patients with GAD that it reduced the risk of 
relapse compared with placebo, during 24 weeks of randomized treatment following 8 
weeks of open-label treatment. (Feltner & Wittchen, 2008) 
7.7 Tiagabine 
The selective GABA reuptake inhibitor tiagabin has been studied in 3 large placebo-
controlled trials in 1830 patients with GAD and no significant difference from placebo was 
showen, moreover side effects were too high that %47 of patients were drop out. It seem 
hard to justify the use of tiagabine for GAD. (Pollack& Tiller ,2008) 
7.8 Agomelatine 
Agomelatine  a novel agent that acts on melatonergic and serotonergic receptors was 
assessed on a  randomized, double-blind, placebo-controlled trial on one hundred twenty-
one patients with GAD with no comorbid disorders.The patients  were randomized to 
agomelatine (25-50 mg/d) or placebo for 12 weeks. The primary outcome measure was the 
Hamilton Anxiety Rating Scale, whereas secondary outcome measures included the Clinical 
Global Impression scales. Analysis of covariance of change in the last Hamilton Anxiety 
Rating Scale total score from baseline demonstrated significant superiority of agomelatine 25 
to 50 mg as compared with placebo.Safety analysis indicated that agomelatine was tolerated 
as well as placebo and was devoid of discontinuation emergent symptoms. This study 
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8. Adequate and poor response to pharmacotherapy: Switching medication 
and augmentation strategies 
In most studies, response is commonly defined as a ≥50% reduction on the commonly used 
standard scales. This definition is also arbitrary, because that cannot be applied for all 
disorders. Assessment of  changes on disease-specific rating scales and measures of global 
illness severity and improvement, social, occupational, and academic functioning, and 
quality of life should be performed. Remission implies not only the relief of symptoms but 
also restoration of patients to their premorbid high level of functioning, including 
resumption of family, social, and work-related role.  
Treatment resistance patient could be defined as a patient who had a standard treatment for 
a minimum of 6 weeks without showing response. Before a treatment is considered as 
failure it should be ascertained that the diagnosis is correct,  the patient is compliant with 
therapy, the dosage prescribed is therapeutic and there has been an adequate trial period. 
Comorbid personality disorders such as borderline personality disorder,  depression and 
substance abuse may be associated with poor outcome. Coocurrence of GAD with medical 
disorders such as heart disease and gastrointestinal and chronic pain disorders causes an 
extended clinical course and poorer outcome than patients with GAD alone (Harter et al., 
2003; Bowen et al., 2000; McWilliams et al., 2003; Roy-Byrne et al., 2008). 
If partial response is not seen after 4–6 weeks, there is still a chance that the patient will 
respond after another 4–6 weeks of therapy with increased dose. When initial treatment 
fails,the psychiatrist can either augment the current treatment by adding another agent (in 
the case of pharmacotherapy) or another modality (i.e., add CBT if the patient is already 
receiving pharmacotherapy, or add pharmacotherapy if the patient is already receiving 
CBT) , or they can decide to switch to a different medication or therapeutic modality. 
Augmentation is generally a reasonable approach if some significant benefits were observed 
with the original treatment . On the other hand, if the original treatment failed to provide 
any significant alleviation of the patient’s symptoms, a switch in treatment may be more 
useful. Treatment resistance are usually based on clinical judgment , “augmentation and 
switching studies” are lacking. Low doses of risperidone have been shown to  improve in 
anxiety symptoms when added to initial treatment in patients who had not responded to 
first-line anxiolytic drugs. (Brawman& Knapp ,2005) A study of quetiapine augmentation of 
paroxetine did not provide evidence as an augmenting agent in GAD.(Simon & 
Connor,2008). Olanzapine has shown similar augmentation effects when added to 
fluoxetine in patients with refractory GAD, although this efficacy was achieved at the 
expense of substantial weight gain.(Pollack&Simon, 2006). Other augmentation strategies 
might include addition of a benzodiazepine or other GABAergic drug to an antidepressant. 
Augmentation of medication with cognitive-behavioral therapy (CBT) has not been studied 
meaningfully in GAD, and its benefit still awaits adequate evaluation. 
9. Maintenance treatment 
Because GAD is a chronic illness, maintenance treatment is required and it is showen that 
stopping acute treatment with anxiolytic after 4 weeks, %60 to 80 patients led to relapse 
within a year. (Rickels &Schweizer, 1990). In a study, even after 6 months  of buspirone 
treatment for GAD, stopping treatment led to relapse of %25 within a month. (Rickels 
&Schweizer, 1988) After treating with essitalopram for 12 weeks, the patients randomized to 
essitalopram or placebo up to 76 weeks and the relapse rates were %19 and %56, 
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respectively. (Allgulander&Florea, 2006). Likely, After 8 weeks of treatment with 
paroxetine, the patients were randomized for 24 weeks and the relapse rates were%10,9 and 
%39,9. (Davidson&Wittchen, 2008). GAD requires long-term treatment that remission can 
take several moths and stopping medication increases the risk of relapse within the first year 
of initiating treatment.  
10. Conclusion 
It is recommended that the first-line treatment for patients with GAD should consist of an 
antidepressant, such as SSRI (paroxetine and essitalopram)  or SNRI (venlafaxine and 
duloksetine). On the other hand  they have efficacy limitations, including lack of response, 
lack of full remission, risk of relapse and adverse effects. This means that there is a need for 
alternative treatment options.  Following the first-line treatment in case of inappropriate 
response; 1) increasing the dose of the SSRI/SNRI, 2)switching to a same class or different 
class agent or 3) augmentation therapy may be considered.The strategy of augmentation 
SSRIs/SNRIs with atypical antipsychotics may be useful in improving the rates of remission 
but randomized controlled studies are needed. 
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